Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evaluation of the Efficacy of Cryopreserved Human Umbilical Cord Tissue Allograft for the Supplementation of Cartilage Defects Associated to Knee Osteoarthritis: An Observational Data Collection Study

Version 1 : Received: 20 July 2022 / Approved: 22 July 2022 / Online: 22 July 2022 (13:08:45 CEST)

How to cite: Davis, J.; Martin, S.; Sheinkop, M.; Barrett, T. Evaluation of the Efficacy of Cryopreserved Human Umbilical Cord Tissue Allograft for the Supplementation of Cartilage Defects Associated to Knee Osteoarthritis: An Observational Data Collection Study. Preprints 2022, 2022070337. https://doi.org/10.20944/preprints202207.0337.v1 Davis, J.; Martin, S.; Sheinkop, M.; Barrett, T. Evaluation of the Efficacy of Cryopreserved Human Umbilical Cord Tissue Allograft for the Supplementation of Cartilage Defects Associated to Knee Osteoarthritis: An Observational Data Collection Study. Preprints 2022, 2022070337. https://doi.org/10.20944/preprints202207.0337.v1

Abstract

The primary objective of this study is to report the initial efficacy data observed with the use of cryopreserved human umbilical tissue allograft for the supplementation of cartilage defects in patients with symptomatic knee osteoarthritis. Our primary endpoints were pain, stiffness, and functional recovery scores. In this ongoing study, 55 participants (age 56-93 years) received a single Wharton's jelly tissue allograft application. The study dose consisted of 150mg of Wharton's jelly allograft suspended in approximately 2mL of sterile Sodium Chloride 0.9% solution (normal saline). Each study knee application was performed under ultrasound guidance in a physician's office. The research methodology consisted of NPRS scores and WOMAC subsection scores including pain, stiffness, and physical function. Study enrollment consisted of 55 patients followed for a post-application duration of 90 days. No adverse events or adverse reactions were reported. The results demonstrated statistically significant improvements of NPRS and WOMAC in initial versus 90-day examination. The data represents Wharton's jelly tissue allograft applications are a safe, non-surgical, and efficacious for patients with symptomatic articular cartilage defects associated with osteoarthritis of the knee. 

Keywords

Wharton's jelly; Regenerative Medicine; Osteoarthritis; Cartilage Defects

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.